Literature DB >> 15069387

Innate immunity and toll-like receptors: clinical implications of basic science research.

Maria T Abreu1, Moshe Arditi.   

Abstract

Humans are constantly exposed to a wide variety of microorganisms that can cause infection. In self-defense, the human host has evolved complex protective mechanisms, and Toll-like receptors (TLRs) have emerged as a central point in defense. These receptors bind molecular structures that are expressed by microbes but are not expressed by the human host, eg, lipopolysaccharides (LPS) or double-stranded RNA (dsRNA). Activation of these receptors initiates an inflammatory cascade that attempts to clear the offending pathogen and set in motion a specific adaptive immune response. Defects in sensing of pathogens may predispose the host to recurrent infections. The relative rarity of these syndromes of defective innate immunity, however, speaks to the redundancy in sensing of pathogens by the innate immune system. More common, polymorphisms in TLR4 are associated with increased predisposition to severe and recurrent infections but protection against atherosclerotic disease due to diminished inflammation. Toll-like receptor signaling may also contribute to the pathophysiology of disease and injure the host by activating a deleterious immune response such as in sepsis or inflammatory bowel disease (IBD). The focus of this article is to describe the role of TLRs in the innate immune response in health and disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15069387     DOI: 10.1016/j.jpeds.2004.01.057

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  42 in total

1.  Membrane-bound toll-like receptors are overexpressed in peripheral blood and synovial fluid mononuclear cells of enthesitis-related arthritis category of juvenile idiopathic arthritis (JIA–ERA) patients and lead to secretion of inflammatory mediators.

Authors:  Arpita Myles; Mujeeb T Rahman; Amita Aggarwal
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

2.  A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation.

Authors:  Anne Månsson; Mikael Adner; Ulf Höckerfelt; Lars-Olaf Cardell
Journal:  Immunology       Date:  2006-06-16       Impact factor: 7.397

3.  It all happens between Toll receptors and caspase 1.

Authors:  Manuel Sanchez-Alavez; Tamas Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-01       Impact factor: 11.205

4.  Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors.

Authors:  Gabriel Vinderola; Chantal Matar; Gabriela Perdigon
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

5.  Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment.

Authors:  Denise Richardt-Pargmann; Miriam Wechsler; Arthur M Krieg; Jörg Vollmer; Marion Jurk
Journal:  Immunobiology       Date:  2010-04-09       Impact factor: 3.144

6.  Coxsackievirus B3 induction of NFAT: requirement for myocarditis susceptibility.

Authors:  S A Huber; M Rincon
Journal:  Virology       Date:  2008-09-30       Impact factor: 3.616

Review 7.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

8.  Lipoteichoic acid is important in innate immune responses to gram-positive bacteria.

Authors:  Ho Seong Seo; Suzanne M Michalek; Moon H Nahm
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

9.  The Effects of Lactobacillus rhamnosus on the Prevention of Asthma in a Murine Model.

Authors:  Jinho Yu; Seong-Ok Jang; Byoung-Ju Kim; Young-Hwa Song; Ji-Won Kwon; Mi-Jin Kang; Won-Ah Choi; Hyun-Don Jung; Soo-Jong Hong
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-19       Impact factor: 5.764

Review 10.  Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.

Authors:  Robert S Parker; Gilles Clermont
Journal:  J R Soc Interface       Date:  2010-02-10       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.